Cell Therapies, Cancer & Rare Diseases

Cell Therapies, Cancer & Rare Diseases
  • Pininvest Analysis

Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement

By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information

Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)

Take a closer look

Cell Therapies, Cancer & Rare Diseases • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
Adaptimmune Therapeutics ADAP NASDAQ Health Care Biopharmaceuticals USD 4.23 444 M -66.2% 77%   1% -74%
Amgen Inc. AMGN NASDAQ Health Care Biopharmaceuticals USD 178.30 111 B 5.1% 22%   1% -16%
Bellicum Pharmaceuticals BLCM NASDAQ Health Care Biopharmaceuticals USD 3.03 134 M -57.9% 65%   1% -71%
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 136.12 7.5 B -16.3% 53%   3% -54%
Celgene CELG NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 93.10 65 B 4.4% 35%   2% -37%
Cellectis SA CLLS NASDAQ Health Care Biopharmaceuticals USD 19.75 838 M -30.8% 39%   2% -50%
Celyad (ADR) CYAD NASDAQ Health Care Biopharmaceuticals USD 20.50 245 M -31.6% 69%   1% -54%
Clovis Oncology, Inc. CLVS NASDAQ Health Care Biopharmaceuticals USD 19.87 1.1 B -55.9% 77%   1% -78%
Corvus Pharmaceuticals CRVS NASDAQ Health Care Biopharmaceuticals USD 4.58 134 M -53.3% 63%   1% -76%
CRISPR Therapeutics CRSP NASDAQ Health Care Gene Editing - Cell Therapies USD 38.57 2.0 B -19.3% 72%   5% -69%
Editas Medicine EDIT NASDAQ Health Care Gene Editing - Cell Therapies USD 27.01 1.3 B -15.0% 66%   5% -56%
Gilead Sciences Inc. GILD NASDAQ Health Care Biopharmaceuticals USD 62.80 80 B -11.1% 25%   1% -23%
Immunogen IMGN NASDAQ Health Care Biopharmaceuticals USD 2.43 363 M -76.5% 93%   1% -81%
Intellia Therapeutics NTLA NASDAQ Health Care Biopharmaceuticals USD 16.68 754 M -18.6% 68%   4% -65%
Intercept Pharmaceuticals ICPT NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 91.23 2.7 B 37.9% 59%   5% -33%
Invitae Corporation NVTA NYSE Health Care Medical Laboratories & Research USD 23.50 1.8 B 325.0% 67%   21% -49%
MacroGenics MGNX NASDAQ Health Care Biopharmaceuticals USD 16.50 805 M -28.4% 98%   3% -53%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 1.09 86 M -72.7% 96%   1% -76%
Neos Therapeutics NEOS NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 2.23 111 M -73.1% 68%   1% -82%
Novartis NVS NYSE Health Care Drug Manufacturers - Diversified USD 77.82 180 B 19.4% 21%   1% -22%
Regeneron Pharmaceuticals Inc. REGN NASDAQ Health Care Biopharmaceuticals USD 340.46 37 B 7.7% 31%   2% -24%
REGENXBIO RGNX NASDAQ Health Care Gene Editing - Cell Therapies USD 52.58 1.9 B 43.3% 64%   7% -52%
Sangamo Therapeutics SGMO NASDAQ Health Care Gene Editing - Cell Therapies USD 11.88 1.2 B -31.3% 86%   4% -59%
Spark Therapeutics ONCE NASDAQ Health Care Biopharmaceuticals USD 110.67 4.2 B 49.9% 98%   8% -62%
uniQure QURE NASDAQ Health Care Gene Editing - Cell Therapies USD 54.70 2.1 B 83.6% 72%   9% -47%
Vericel VCEL NASDAQ Health Care Gene Editing - Cell Therapies USD 17.61 770 M 47.4% 73%   5% -38%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 4.16 675 M -3.7% 80%   4% -67%